This content is only available within our institutional offering.
05 Mar 2019
Rude Health - finnCap Life Sciences quarterly sector note
Allergy Therapeutics plc (AGY:LON), 21.2 | Avacta Group PLC (AVCT:LON), 200 | Bioventix Plc (BVXP:LON), 4,250 | Byotrol plc (BYOT:LON), 6.2 | Cambridge Cognition Holdings Plc (COG:LON), 74.0 | InnovaDerma PLC (IDP:LON), 41.5 | Inspiration Healthcare Group PLC (IHC:LON), 111 | Omega Diagnostics Group PLC (ODX:LON), 89.0 | SDI Group plc (SDI:LON), 164 | Synairgen plc (SNG:LON), 168 | Tristel Plc (TSTL:LON), 609 | ANGLE plc (AGL:LON), 77.5 | Destiny Pharma Plc (DEST:LON), 106
-
-
-
Mark Brewer
-
32 pages
-


Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Rude Health - finnCap Life Sciences quarterly sector note
Allergy Therapeutics plc (AGY:LON), 21.2 | Avacta Group PLC (AVCT:LON), 200 | Bioventix Plc (BVXP:LON), 4,250 | Byotrol plc (BYOT:LON), 6.2 | Cambridge Cognition Holdings Plc (COG:LON), 74.0 | InnovaDerma PLC (IDP:LON), 41.5 | Inspiration Healthcare Group PLC (IHC:LON), 111 | Omega Diagnostics Group PLC (ODX:LON), 89.0 | SDI Group plc (SDI:LON), 164 | Synairgen plc (SNG:LON), 168 | Tristel Plc (TSTL:LON), 609 | ANGLE plc (AGL:LON), 77.5 | Destiny Pharma Plc (DEST:LON), 106
- Published:
05 Mar 2019 -
Author:
Mark Brewer -
Pages:
32 -
AIM Healthcare Index is up 10% year to date, outperforming the AIM All Share (+6%) and FT All Share (+7%), having suffered with the broader market pull back in Q4 2018, in which AIM Healthcare fell 18%. This compared with a 22% decline in the AIM All Share and 11% decline in the FT All Share. In the past quarter, the AIM Health sector has fallen 1%, not helped by the FDA’s rejection of Motif Bio’s NDA for iclaprim. However, there were 14 finnLife 50 stocks that exhibited double-digit percentage increases, most notable of which are Futura Medica (+112%), Avacta* (+82%), OptiBiotix* (+35%), hVIVO (+34%), Instem (+34%) and ANGLE* (+29%) in the past three months